|Bid||0.6368 x 268600|
|Ask||0.6492 x 258400|
|Day's Range||0.6304 - 0.6564|
|52 Week Range||0.2530 - 1.7845|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 27, 2023 - Mar 31, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
BOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac